WHO estimates that 62 million cases of gonorrhea occur annually worldwide, the result of infection by N. gonorrhoeae, a gram-negative bacterium. Often, gonorrhea has no symptoms, especially among women, but undiagnosed and untreated infection can cause serious long-term complications. Over-treatment is a major concern because of widespread N. gonorrhea antibiotic resistance, and some infected patients never receive treatment as they fail to return for their test results. For these reasons, accurate screening tests are important for disease management. Gram stain evaluation and culture isolation remains the gold standard test with high sensitivity and specificity, but the procedure requires highly trained staff and its performance is affected by specimen transport. Nucleic acid amplification has higher sensitivity, however, it can cross-react with other Neisseria species. Rapid tests offer an alternative that allows patients to be treated at the time of the initial visit due to the short time to result.